Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-04-24
2010-12-07
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S116000
Reexamination Certificate
active
07846929
ABSTRACT:
Compounds of Formulas Ia and Ib, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
REFERENCES:
patent: 3475429 (1969-10-01), Woitun et al.
patent: 3661908 (1972-05-01), Woitun et al.
patent: 3763156 (1973-10-01), Woitun et al.
patent: 3838121 (1974-09-01), Woitun et al.
patent: 4007187 (1977-02-01), Fauran et al.
patent: 4146716 (1979-03-01), Cox et al.
patent: 4196207 (1980-04-01), Webber et al.
patent: 6608053 (2003-08-01), Hayakawa et al.
patent: 6838457 (2005-01-01), Hayakawa et al.
patent: 7037915 (2006-05-01), Hayakawa et al.
patent: 7173029 (2007-02-01), Hayakawa et al.
patent: 1277738 (2003-01-01), None
patent: 1393161 (1975-05-01), None
patent: WO 2004/065391 (2004-08-01), None
patent: WO 2006/046031 (2006-05-01), None
patent: WO 2006/046035 (2006-05-01), None
patent: WO 2006/046040 (2006-05-01), None
Cancer and Metastasis Reviews (1998), 17(1), 91-106.
Science (1999), vol. 286, 531-537.
Byrn et al., Solid-State Chemistry of Drugs, Second Edition, 1999, pp. 233-247.
Briel et al. “Selective Nucleophilic Replacement of the Benzylsulfanyl Group in 2, 4-Disulfanyl-substituted Thieno[2,3-d]pyrimidin-6-carboxylic Acid Derivatives by Secondary Amines”,Journal Heterocyclic Chem. , 42(5), 841-846, Jul.-Aug. 2005.
Bachman et al., “ThePIK3CAgene is mutated with high frequency in human breast cancers”,Cancer Biology&Therapy, 3(8), 772-775, Aug. 2004.
Berge et al., “Pharmaceutical Salts”,Journal of Pharmaceutical Sciences,66(1), Jan. 1-19, 1977.
C. Garcia-Echeverria et al., “Drug discovery approaches targeting the PI3/Akt pathway in cancer”,Oncogene, 27, 5511-5526, 2008.
Kang et al., “Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic”,PNAS, 102(3), 802-807, Jan. 18, 2005.
Raynaud et al., “Biological properties of potent inhibitors of class I phophatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941”,Mol. Cancer Ther., 8(7), 1725-1738, Jul. 2009.
Samuels et al., “High frequency of mutations of thePIK3CAgene in human cancers”,Science, 304, 554, Apr. 23, 2004.
Shayesteh et al., “PIK3CAis implicated as an oncogene in ovarian cancer”,Nature Genetics, 21, 99-102, Jan. 1999.
Workman et al., “Drugging the PI3 kinome”,Nature Biotechnology, 24(7), 794-796, Jul. 2006.
Yap et al., “Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises”,Current Opinion in Pharmacology, 8, 393-412, 2008.
Bayliss Tracy
Castanedo Georgette
Dotson Jennafer
Folkes Adrian
Goldsmith Richard
Anderson Rebecca L
Genentech Inc.
Piramed Limited
Viksnins Harris & Padys PLLP
LandOfFree
Phosphoinositide 3-kinase inhibitor compounds and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phosphoinositide 3-kinase inhibitor compounds and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphoinositide 3-kinase inhibitor compounds and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4181190